Stage III Non-small Cell Lung Cancer Clinical Trial
Official title:
A Phase II Trial of Tislelizumab as Consolidation Therapy in Patients With Locally Advanced Non-Small Cell Lung Cancer Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
The phase II Study is to explore the efficacy and safety of Tislelizumab as consolidation therapy in patients with locally advanced non-small cell lung cancer who have not progressed following neoadjuvant chemotherapy plus Tislelizumab ± Bevacizumab and definitive concurrent chemoradiation therapy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05488626 -
Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer
|
N/A | |
| Recruiting |
NCT02076282 -
MRI Optimization Study in Stage III NSCLC
|
N/A | |
| Terminated |
NCT01577212 -
Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy
|
Phase 2 | |
| Withdrawn |
NCT01336543 -
Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Completed |
NCT01102231 -
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Completed |
NCT00019006 -
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT06082492 -
The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT03049618 -
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
|
Phase 2 | |
| Recruiting |
NCT03077854 -
Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial
|
N/A | |
| Recruiting |
NCT05157542 -
Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC
|
Phase 1 | |
| Recruiting |
NCT00938418 -
Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05361174 -
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03048500 -
Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
| Not yet recruiting |
NCT05891080 -
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
|
Phase 2 | |
| Active, not recruiting |
NCT01948141 -
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
|
Phase 2 | |
| Completed |
NCT01282437 -
Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC
|
Phase 3 | |
| Recruiting |
NCT05631574 -
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
|
Phase 1 | |
| Recruiting |
NCT05157503 -
Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"
|
||
| Active, not recruiting |
NCT06102057 -
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
|
Phase 2 | |
| Recruiting |
NCT04984148 -
Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC
|